Category Archives: ALS Treatment

The annual walk raised more than $80,000 locally last year and due to COVID-19 it will be held online on June 21. THUNDER BAY - Things will look a little different this year during the annual Walk to End ALS, but organizers and family members are hopeful they can still build on the momentum from previous years and continue the fight against this debilitating disease. I think last year we really got a good idea of how many people are affected by ALS directly and indirectly and how much support people are willing to provide, said Matthew Mustapic, whos father was diagnosed with ALS last year. Continue reading →

- Amylyx Remains on Track to Share Topline PEGASUS Trial Results by Q1 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimers disease and other neurodegenerative diseases, today announced it has completed enrollment in the Phase II PEGASUS trial assessing AMX0035 in individuals with Alzheimers disease. Continue reading →

A new study brings hope for people with ALS. Immunotherapy may dramatically slow down the progression of the disease, it shows. The neurodegenerative condition amyotrophic lateral sclerosis (ALS) affects nerve cells, which control the movement of muscles, in the brain and spinal cord. Continue reading →

The ALS Association and I AM ALS have awarded BrainStorm Cell Therapeutics $500,000 to support an amyotrophic lateral sclerosis (ALS) biomarker study based on the biotechnology companys pivotal trial into its NurOwn therapy. Continue reading →

June 08, 2020 16:00 ET | Source: Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif.,, June 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Continue reading →

Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Continue reading →

Amyotrophic lateral sclerosis (ALS) is a disease characterized by the progressive loss of motor neurons, or the nerve cells involved in the control of the voluntary muscles. This leads to problems controlling muscles, which causes them to gradually weaken. Continue reading →

New research makes a discovery that suggests a clear approach for developing a potential therapy for ALS. Continue reading →

To expedite positive patient outcomes, U.S. Sen. Martha McSally (R-AZ) on June 3 introduced a GOP-led bill that would establish a time-limited provisional approval pathway for certain drugs and biological products. Continue reading →

June 09, 2020 16:30 ET | Source: Denali Therapeutics Inc. SOUTH SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the results from its Phase 1b studies with small molecule RIPK1 inhibitor DNL747 in Alzheimers disease and ALS, and provided a broad RIPK1 program update including DNL788 and DNL758. Continue reading →